Study on analgesic effect of three point block of dexmedetomidine combined with Ropivacaine in modified radical surgery of breast cancer under general anesthesia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077127

Enrollment

Unknown

Registered

2023-10-31

Start date

2023-11-01

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

General anesthesia group:General anesthesia

Ropivacaine group:Three-point nerve block was administered with ropivacaine under general anesthesia

Dexmedetomidine combined with ropivacaine group:Three-point nerve block was administered with ropivacaine combined with dexmedetomidine under general anesthesia

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age <75 years old 2. BMI 18.5-28 kg/m2 3. ASA grade I - III 4. female

Exclusion criteria

Exclusion criteria: 1: Allergic to anesthetics 2: Severe mental illness or endocrine disorder 3: Cancer metastasizes to other organs 4: Hematopoietic insufficiency/liver and kidney insufficiency/heart insufficiency 5: Hypertensive patients with irregular preoperative control of blood pressure 6: Patients who are unable to understand or use a digital pain scoring system or who refuse to use a controlled analgesia (PCA) pump 7: Patients who are opioid dependent.

Design outcomes

Primary

Measure	Time frame
Dosage of analgesics used during operation and 24h after operation;VAS scores;	—

Secondary

Measure	Time frame
Blood cortisol concentration; IL-6;mini-mental state examination;	—

Countries

China

Contacts

Public ContactZou Xia

The People's Hospital of Guangxi Zhuang Autonomous Region

815117450@qq.com+86 156 7678 1025

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026